NICE recommends Lundbeck’s Selincro for alcohol dependence

2 October 2014

Today’s announcement that the UK’s National Institute for Health and Care Excellence (NICE) recommends the use of Selincro (nalmefene) will be welcome news for around 600,000 alcohol dependent people in England who may be eligible for the treatment, says the drug’s manufacturer, Danish CNS specialist Lundbeck (LUN: CO).

For the first time, dependent drinkers unable to reduce their consumption of alcohol on their own can take a pill, which, along with counselling (medical advice and support), may help more than halve the amount they drink (by an average of 61% after six months). This is different from other medicines available for the condition, which are licensed to help patients maintain abstinence from alcohol. The reduction of alcohol consumption of 61% seen in the key trials is equivalent to approximately 28 fewer bottles of wine consumed per person over one month.

Selincro found to be clinically and cost effective option

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK